Good Market Growth Should Continue for Contrast Media
Dec. 15, 2004
The market for medical imaging contrast media increased 7% in 2004 reaching $1.41 billion. This growth rate will increase to 8.6% in 2004 with sales of $1.54 billion. Growth rates of 9%-12% are forecast between 2005-2009, with sales increasing to $2.58 billion by 2009.
Although pricing of contrast agents for CT and MR has continued to diminish with time, the huge increase in procedure volume during the past five years in both modalities has made it possible for manufacturers to benefit from economies of scale. Many products have assumed a generic character, with pricing based on group purchasing contracts that tend to minimize the differences between products. The two largest contracts are Novation and Premier. Novation includes the VA, UHS and UHC (University Hospital System Consortium). Although UHC is a small hospital group, each institution uses more contrast agents.
The trend toward bundling products provided by a single manufacturer into a group-purchasing contract has had great leverage on pricing. This has gradually forced prices down to about $20 a dose for x-ray nonionic media and $30 a dose for MR contrast agents. However, prices appear to have stabilized at these levels.
New contrast agents in development should offer manufacturers greater margins when these products are approved. Specialized products for vascular imaging hold good potential because of better persistence and improved imaging capability compared with conventional contrast agents. Since vascular imaging is performed routinely in many CT and MR procedures, the added revenue will be significant to companies offering these products. Other new targeted contrast agents for detecting thrombus and atherosclerotic plaque are also being actively developed. As these products are introduced, it will stimulate further investment in new technology that will provide continued market stimulus.
BIO-TECH SYSTEMS, INC., founded in 1980, provides clients with market research services in the healthcare field. This focuses on strategic planning, market research and development of new business opportunities. Bio Tech specializes in product and market evaluation where technical insight is important as well as the ability to communicate with many levels of management and end-users. One objective is to assess technological risk and target new products and services effectively in order to generate the best market response. Bio-Tech's expertise is in medical imaging and radioisotope products covering a broad range of diagnostic and therapeutic applications. For further details and information, please visit us at: